New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
06:33 EDTANGOAngioDynamics wins $74.9M in case against biolitec AG
AngioDynamics announced a recent court action in its legal case against biolitec AG. On March 18, the U.S. District Court for the District of Massachusetts entered a judgment awarding AngioDynamics $74.9M in damages based on AngioDynamics' claims that biolitec AG, Biomed Technology Holdings Limited and Wolfgang Neuberger tortiously interfered with its U.S. subsidiary, biolitec Inc.'s, contractual obligations. The dispute originally began when AngioDynamics asserted biolitec Inc. breached a contractual agreement to defend and indemnify AngioDynamics against patent infringement claims by third parties arising out of the use of laser vein ablation products supplied by biolitec.
News For ANGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
07:05 EDTANGONeedham to hold a conference
Subscribe for More Information
April 10, 2015
16:14 EDTANGOOn The Fly: Closing Wrap
Subscribe for More Information
08:38 EDTANGOAngioDynamics weakness a buying opportunity, says Canaccord
Canaccord said the weakness in AngioDynamics following its soft Q3 results is a buying opportunity. The firm cited negative currency impact, a slowdown in EVLT procedures, its Morpheus PICC market withdrawal, and the delay in its second generation AngioVac release. Canaccord likes the company's free cash flow generation and improved inventory management and reiterated its Buy rating, but lowered its price target to $20 from $22 on AngioDynamics shares.
April 9, 2015
16:44 EDTANGOAngioDynamics down 6% after weaker than expected Q3 results, guidance
Subscribe for More Information
16:09 EDTANGOAngioDynamics re-entering embolization market with EmboMedics pact
Subscribe for More Information
16:06 EDTANGOAngioDynamics now sees FY15 adjusted EPS 57c-60c, consensus 68c
Subscribe for More Information
16:06 EDTANGOAngioDynamics lowers FY15 revenue view to $356M-$360M from $362M-$368M
The company said, "We believe the action we took in the third fiscal quarter to voluntary recall/discontinue our Morpheus PICC product line will drive longer-term strategic benefits; however, its short term impact coupled with the headwinds due to foreign currency exchange has resulted in a revision of net sales for fiscal year 2015 to a range of $356M-$360M from our prior outlook of a range of $362M-$368M. At the midpoint, excluding the supply agreement and based on constant currency, this represents an increase of 3% over fiscal year 2014."
16:05 EDTANGOAngioDynamics sees Q4 adjusted EPS 13c-16c, consensus 19c
Sees Q4 revenue $90M-$94M, 3% at the top end on a constant currency basis and excluding its supply agreement.
16:03 EDTANGOAngioDynamics reports Q3 adjusted EPS 12c, consensus 16c
Subscribe for More Information
15:20 EDTANGONotable companies reporting after market close
Subscribe for More Information
13:45 EDTANGOAngioDynamics technical commentary before earnings
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use